Table 2: Tumor characteristics and treatment assignment in the cohort population.
|
Variable |
|
Non-cirrhotic n=101 |
|
Cirrhotic n=382 |
P value |
|
|
|
N |
|
N |
|
||
|
Screening program (yes) |
98 |
19(19.4%) |
368 |
167(45.3%) |
P<0.001 |
|
|
Tumor characteristics |
||||||
|
BCLC stage |
0 |
99 |
1(1%) |
369 |
29 (7.9%) |
P<0.001 |
|
A |
33(33.3%) |
160(43.4%) |
||||
|
B |
39(39.4%) |
86(23.3%) |
||||
|
C |
26(26.3%) |
70(19%) |
||||
|
D |
0(0%) |
24 (6.5%) |
||||
|
First line therapy |
Transplant |
101 |
3(3%) |
382 |
30(7.9%) |
P<0.001 |
|
Surgery |
41(40.6%) |
57(14.9%) |
||||
|
Microwave ablation |
11(10.9%) |
57(14.9%) |
||||
|
Loco regional therapy |
12(11.9%) |
80(20.9%) |
||||
|
Systemic therapy |
16(15.8%) |
47(12.3%) |
||||
|
Best supportive care |
18(17.8%) |
111(29.1%) |
||||
|
TTV, cm3 (median and IQR) |
41 |
1456(253- 10348) |
57 |
179(36-523) |
P<0.001 |
|
Values are presented as n (%), mean (SD, standard deviation), median (IQR, interquartile range).
The p values apply to the cirrhotic versus non-cirrhotic group. P value was assumed to be significant when <0.05.
N represents the patients’ number with available data.
Locoregional therapy included TACE, yttrium‐90 radioembolization and external radiotherapy ± TACE, systemic therapy included treatment with Sorafenib and Nivolumab.
SD: Standard Deviation; IQR: Interquartile Range; BCLC: tumor stage according to Barcelona Clinic Liver Cancer staging system; TTV: Total Tumor Volume, applies only for patients who underwent surgery.